Status of flavonols as P-glycoprotein inhibitors in cancer chemotherapy

Current Cancer Therapy Reviews

Volumn 5, Issue 2, 2009, Pages 89-99

  Bansal, Tripta ^a,b   Jaggi, Manu ^b   Khar, Roop K ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

Chemotherapy; Flavonoids; Flavonols; Multi drug resistance; P glycoprotein; Pharmacokinetic

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APRICOT EXTRACT; BIRICODAR; CAMPTOTHECIN; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; EPIPODOPHYLLOTOXIN; FLAVONOL DERIVATIVE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GRAPEFRUIT EXTRACT; IRINOTECAN; KAEMPFEROL; LOPERAMIDE; NARINGENIN; ORANGE EXTRACT; PACLITAXEL; PEPPERMINT OIL; PLANT EXTRACT; QUERCETIN; ROSMARINUS OFFICINALIS EXTRACT; STRAWBERRY EXTRACT; TAMOXIFEN; TARIQUIDAR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; APRICOT; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME INHIBITION; FOOD; GRAPEFRUIT JUICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; ORANGE (FRUIT); ORANGE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; STRAWBERRY; TISSUE DISTRIBUTION;

EID: 68449098665     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339409788166742     Document Type: Review

References (138)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
2. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
3. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-83.
4. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
5. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Journees Galeniques 2001; 94: 9-16.
6. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of Pglycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Del Rev 1997; 25: 129-57.
7. Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-8.
8. Tandon VR, Kapoor B, Bano G, et al. P-glycoprotein: Pharmacological relevance. Indian J Pharmacol 2006; 38: 13-24.
9. Varma MV, Perumal OP, Panchagnula R. Functional role of Pglycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol 2006; 10: 367-73.
10. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoproteinmediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-9.
11. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-602.
12. Thiebaut F, Tsumo T, Hamada H, et al. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
13. Croop JM, Raymond M, Haber D, et al. The three mouse multidmg resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346-50.
14. Arceci RJ, Croop JM, Horwitz S, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350-4.
15. Joly B, Fardel O, Cecchelli R, et al. Selective drug transport and Pglycoprotein activity in an in vitro blood-brain barrier model. Tox In vitro 1995; 9: 357-64.
16. Fardel O, Lecureur V, Guillouzo A. The P-Glycoprotein multidrug transporter. Gen Pharmac 1996; 27: 1283-91.
17. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10: 159-65.
18. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006; 27: 392-400.
19. Sharom FJ. The P-glycoprotein efflux pumps: how does it transport drugs? J. Memb Bio 1997; 160: 161-75.
20. Sauna ZE, Smith MM, Muller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioener Biomemb 2001; 33: 481-91.
21. Loo TW, Clarke DM. Do drug substrates enter the common drugbinding pocket of P-glycoprotein through "gates"? Biochem Biophys Res Commun 2005; 329: 419-22.
22. Varma M, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-59.
23. Schoenhard GL. Inhibitors of ABC drug transporters at the bloodbrain barrier In: US: Pain Therapeutics, Inc.; 2006.
24. Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 2003; 55: 133-50.
25. Colombo T, Gonzalez Paz O, D'Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73: 866-71.
26. Liscovitch M, Lavie Y. Cancer multidrug resistance: A review of recent drug discovery research. IDrugs 2002; 5: 1-7.
27. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580: 2903-09.
28. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by Dalpha- tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-6.
29. Kabanova AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-79.
30. Zhou S, Lim LY, Chowbay B. Herbal modulation of Pglycoprotein. Drug Metab Rev 2004; 36:57-104.
31. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16:237-46.
32. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 2007; 274: 6204-14.
33. Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007; 59: 1482-503.
34. Brand W, Schutte ME, Williamson G, et al. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 2006; 60: 508-19.
35. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug - herbal interactions. Life Sci 2006; 78: 2146-57.
36. Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004; 278: 119-31.
37. Deferme S, Gelder JV, Augustijns P. Inhibitory effect of fruit extracts on P-glycoprotein related efflux carriers: an in vitro screening. J Pharm Pharmacol 2002; 54: 1213-19.
38. Deferme S, Augustijns P. The effects of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 2003; 55: 153-62.
39. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-41.
40. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006; 78: 2116-30.
41. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131-45.
42. Yang CY, Chao PD, Hou YC, et al. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006; 44: 1572-8.
43. Yoshida N, Takagi A, Kitazawa H, et al. Inhibition of Pglycoprotein- mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol Appl Pharmacol 2005; 209: 167-73.
44. Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007; 12: 664-73.
45. Bailey D, Spence J, Munoz C, Arnold J. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9.
46. Peng SX, Ritchie DM, Cousineau M, et al. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 2006; 95: 1984-93.
47. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000; 22:131-6.
48. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 47-64.
49. Wilkinson GR. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 1997; 27: 129-59.
50. Zhou SF, Gao YH, Wen QJ, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98.
51. Laitinen LA, Tammela PS, Galkin A, et al. Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers. Pharm Res 2004; 21: 1904-16.
52. Narayana KR, Reddy MS, Chaluvadi MR, Krishna DR. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian Journal of Pharmacology 2001; 33: 2-16.
53. Ross SA, Ziska DS, Zhao K, ElSohly MA. Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 2000; 71: 154-161.
54. Manach C, Morand C, Gil-Izquierdo A, et al. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Europ J Clin Nutr 2003; 57: 235-42.
55. Dupuy J, Larrieu G, Sutra JF, et al. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol 2003; 112: 337-47.
56. Choi JS, Choi HK, Shin SC. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 2004; 275: 165-70.
57. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004; 57: 313-8.
58. Wang YH, Chao PD, Hsiu SL, et al. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004; 74: 1191-7.
59. Karyekar CS, Eddington ND, Briglia A, et al. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 2004; 44: 919-27.
60. Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci 2000; 97: 2515-20.
61. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999; 259: 18-24.
62. Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 2007; 10: 319-31.
63. Maki N, Hafkemeyer P, Dey S. Allosteric modulation of human Pglycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 2003; 278: 18132-9.
64. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304: 1258-67.
65. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995; 228: 1020-9.
66. Arora A, Byrem TM, Nair MG, Strasburg GM. Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids. Arch Biochem Biophys 2000; 373: 102-9.
67. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53: 587-96.
68. Boumendjel A, Di Pietro A, Dumontet C, Barron D. Recent advances in the discovery of flavonoids and analogues with high affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 2002; 22: 512-529.
69. Ikegawa T, Ohtani H, Koyabu N, et al. Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 2002; 177: 89-93.
70. Mitsunaga Y, Takanaga H, Matsuo H, et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395:193-201.
71. Chieli E, Romiti N, Cervelli F, Tongiani R. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 1995; 57: 1741-51.
72. Ohtani H, Ikegawa T, Honda Y, et al. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharm Res 2007; 24: 1936-43.
73. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313: 144-9.
74. Takanaga H, Ohnishi A, Yamada S, et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000; 293: 230-6.
75. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34: 459-64.
76. Yoshikawa M, Ikegami Y, Sano K, et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 2004; 4: 25-35.
77. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998; 21: 1062-6.
78. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005; 17: 86-95.
79. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 1994; 48: 1437-45.
80. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol stimulated efflux of 7,12-dimethylbenz(a)-anthracene in multidrugresistant breast cancer cells. Cancer Res 1993; 53: 5977-81.
81. Ferte ́J, Ku ̈hnel J-M, Chapuis G, et al. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure activity relationships. J Med Chem 1999; 42: 478-89.
82. Chiba P, Holzer W, Landau M, et al. Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity. J Med Chem 1998; 41: 4001-11.
83. Ecker G, Huber M, Schmid D, Chiba P. The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol Res 1999; 56: 791-6.
84. Hiessbock R, Wolf C, Richter E, et al. Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines. J Med Chem 1999; 42: 1921-6.
85. Hadjeri M, Barbier M, Ronot X, et al. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J Med Chem 2003; 46: 2125-31.
86. Cooray HC, Janvilisri T, van Veen HW, et al. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 2004; 317: 269-75.
87. van Zanden JJ, Wortelboer HM, Bijlsma S, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005; 69: 699-708.
88. Guengerich FP, Kim HD. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990; 11: 2275-9.
89. Miniscalco A, Landahl J, Regardh CG, et al. Inhibition of dihydropyridine in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992; 261: 1195-8.
90. Choi JS, Shin SC. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm 2005; 292: 149-56.
91. Hsiu SL, Hou YC, Wang YH, et al. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 2002; 72: 227-35.
92. Shapiro AB, Ling V. Stoichiometry of coupling of rhodamine 123 transporter to hydrolysis by human P glycoprotein. Eur J Biochem 1998; 254: 189-93.
93. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65: 2577-82.
94. Allen JD, Van Dort SC, Buitelaar M, et al. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003; 63:1339-44.
95. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-6.
96. Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087-93.
97. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651-6.
98. Schellens JHM, Schinkel AH. Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs. In: US: Cancer Research Ventures Limited; 2006.
99. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999; 43: 454-60.
100. Borst P, Schinkel AH. Genetic dissociation of the function of mammalian P-glycoproteins. Trends Genet 1997; 13: 217-22.
101. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998; 352: 285.
102. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
103. Sparreboom A, Asperen JV, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-5.
104. van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-3.
105. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001; 19: 1160-6.
106. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002; 110: 1309-18.
107. Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin Invest 1997; 100: 2430-6.
108. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
109. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003; 307: 824-8.
110. Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085-92.
111. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007; 24: 1720-8.
112. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24.
113. Youdim KA, Qaiser MZ, Begley DJ, et al. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004; 36: 592-604.
114. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55: 53-81.
115. Walle T, Walle K, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metabol Dispos 1995; 23: 506-12.
116. Schellens JHM, Malingre MM, Marielle C, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000; 12: 103-110.
117. Iyer L, Ramirez J, Shepard DR, et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 2002; 49: 336-41.
118. Tobin PJ, Hong Y, Seale JP, et al. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. J Pharm Pharmacol 2005; 57: 39-45.
119. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 2001; 19: 832-42.
120. Meerum Terwogt JM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5: 3379-84.
121. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-58.
122. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000; 60: 2964-72.
123. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998; 16: 2964-76.
124. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997; 3: 2005-15.
125. Sparreboom A, Planting AS, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999; 10: 719-28.
126. Horio M, Chin KV, Currier SJ, et al. Trans-epithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol Chem 1989; 264: 14880-4.
127. Arimori K, Kuroki N, Hidaka M, et al. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003; 20:910-7.
128. Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996; 56: 1309-14.
129. Wagner D, Spahn-Langguth H, Hanafy, A et al. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev 2001; 50 Suppl 1: S13-31.
130. Plouzek CA, Ciolino HP, Clarke R, Yeh GC. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer 1999; 35: 1541-5.
131. Ikegawa T, Ushigome F, Koyabu N, et al. Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 2000; 160: 21-8.
132. Hu Z, Yang X, Ho PC, et al. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005; 22: 902-14.
133. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J Pharm Sci 2001; 12: 361-7.
134. Wang E, Casciano CN, Clement RP, Johnson WW. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen Pharm Res 2001; 18: 432-8.
135. Gottesman MM. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53747-54.
136. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human tumors. J Natl Canc Inst 1989; 81: 116-24.
137. Arboix M, Paz OG, Colombo T, D'Incalci M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther 1997; 281: 1226-30.
138. Inomata K, Takahashi T, Inoue H, et al. Multidrug resistance inhibitors. In: US: Nisshin Flour Milling Co., Ltd.; 2000.